Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06312774
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-15
First Post:
2024-03-08
Brief Title:
Feasibility of Proteomics in Chronic Lung Disease With Sarcopenia
Sponsor:
University College London
Organization:
University College London
Study Overview
Official Title:
Feasibility Study for Comparative Analysis of Proteome and Single-cell RNA Sequencing in Chronic Lung Disease Patients With and Without Sarcopenia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Sarcopenia the loss of muscle mass and strength with ageing is a prevalent condition in older adults particularly those with chronic lung diseases like COPD and interstitial lung disease The condition exacerbates the decline in physical ability leading to decreased mobility impaired quality of life and increased disability Sarcopenias prevalence varies across populations estimated to affect up to 10 of adults over 60 worldwide with higher rates reported in studies employing consensus definitions of sarcopenia The prevalence is even higher in patients with chronic lung diseases reaching up to 266 Sarcopenias impact on health-related quality of life has been widely investigated The condition is associated with various comorbidities including chronic heart failure obesity diabetes and chronic kidney disease all negatively impacting the quality of life
The proposed studys primary aim is to assess the feasibility of the FACS finding assessing confirming severity approach in determining sarcopenias prevalence in the chronic lung disease population FACS includes screening strength measurements and bioelectrical impedance analysis BIA to confirm sarcopenia
The study will also explore potential mechanisms associated with sarcopenia in this population using proteome and single-cell transcriptome profiles These multi-omics approaches provide a comprehensive view of the cellular and molecular changes underlying sarcopeniaIn particular the study will evaluate patient acceptance time efficiency of each test and recruitment effectiveness The outcomes will guide the design and execution of subsequent larger studies and provide preliminary data for power calculation for the full-scale study
The proposed studys primary aim is to assess the feasibility of the FACS finding assessing confirming severity approach in determining sarcopenias prevalence in the chronic lung disease population FACS includes screening strength measurements and bioelectrical impedance analysis BIA to confirm sarcopenia
The study will also explore potential mechanisms associated with sarcopenia in this population using proteome and single-cell transcriptome profiles These multi-omics approaches provide a comprehensive view of the cellular and molecular changes underlying sarcopeniaIn particular the study will evaluate patient acceptance time efficiency of each test and recruitment effectiveness The outcomes will guide the design and execution of subsequent larger studies and provide preliminary data for power calculation for the full-scale study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None